Therapy-resistant depression

References

• Bauer M, Bschor T, Pfennig A et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders in primary care. World J. Biol. Psychiatry8, 67–104 (2007).
   PubMed Web of Science ®Google Scholar
• Little A. Treatment-resistant depression. Am. Fam. Physician80, 167–172 (2009).
   PubMed Web of Science ®Google Scholar
• Bschor T, Adli M. Treatment of depressive disorders. Dtsch Arztebl. Int.105, 782–91 (2008).
   PubMed Web of Science ®Google Scholar
• Taylor MJ, Freemantle N, Geddes JR, Bhagwagar Z. Early onset of selective serotonin reuptake inhibitor antidepressant action. Systematic review and meta-analysis. Arch. Gen. Psychiatry63, 1217–1223 (2006).
   PubMed Web of Science ®Google Scholar
• Klein DN, Santiago NJ. Dysthymia and chronic depression: introduction, classification, risk factors and course. J. Clin. Psychol.59, 807–816 (2003).
   PubMed Web of Science ®Google Scholar
• Bschor T. Diagnosis, differential diagnosis, exclusion of pseudo therapy resistance. In: Treatment Manual of Therapy Resistant Depression. Pharmacotherapy – Somatic Treatment Strategies – Psychotherapy. [in German]. Bschor T (Ed.). Kohlhammer Publisher, Stuttgart, Germany, 17–27 (2008).
   Google Scholar
• Baumann P, Hiemke C, Ulrich S et al. The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry37, 243–265 (2004).
   PubMed Web of Science ®Google Scholar
• Rush AJ, Trivedi MH, Wisniewski SR et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am. J. Psychiatry163, 1905–1917 (2006).
   PubMed Web of Science ®Google Scholar
• Fava M, Rush AJ, Trivedi MH et al. Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. Psychiatr. Clin. North Am.26, 457–494 (2003).
   PubMed Web of Science ®Google Scholar
• Trivedi MH, Rush AJ, Wisniewski SR et al.; STAR*D study team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am. J. Psychiatry163, 28–40 (2006).
   PubMed Web of Science ®Google Scholar
• Rush AJ, Trivedi MH, Wisniewski SR et al.; STAR*D study team. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N. Engl. J. Med.354, 1231–1242 (2006).
   PubMed Web of Science ®Google Scholar
• Thase ME, Friedman ES, Biggs MM et al. Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report. Am. J. Psychiatry164, 739–752 (2007).
   PubMed Web of Science ®Google Scholar
• Cipriani A, Furukawa TA, Salanti G et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet373, 746–758 (2009).
   PubMed Web of Science ®Google Scholar
• Bschor T, Baethge C. No evidence for switching the antidepressant. Systematic review and meta-analysis of rcts of a common therapeutic strategy. Acta Psychiatr. Scand. (2009) (Epub ahead of print).
   PubMedGoogle Scholar
• Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J. Affect. Disord.58, 19–36 (2000).
   PubMed Web of Science ®Google Scholar
• Riederer P, Lachenmayer L, Laux G. Clinical applications of MAO-inhibitors. Curr. Med. Chem.11, 2033–2043 (2004).
   PubMed Web of Science ®Google Scholar
• Bschor T, Bauer M. Efficacy and mechanisms of action of lithium augmentation in refractory major depression. Curr. Pharm. Des.12, 2985–2992 (2006).
   PubMed Web of Science ®Google Scholar
• Bauer M, Crossley NA, Gerber S, Bschor T. The acute antidepressive effects of lithium: from monotherapy to augmentation therapy in major depression. In: Lithium in Neuropsychiatry. The Comprehensive Guide. Bauer M, Grof P, Müller-Oerlinghausen B (Eds). Informa Healthcare, London, UK, 109–127 (2006).
   Google Scholar
• Bauer M, Bschor T, Kunz D, Berghöfer A, Ströhle A, Müller-Oerlinghausen B. Double-blind, placebo-controlled trial of the use of lithium to augment antidepressant medication in continuation treatment of unipolar major depression. Am. J. Psychiatry157, 1429–1435 (2000).
   PubMed Web of Science ®Google Scholar
• Bschor T, Berghöfer A, Ströhle A et al. How long should the lithium augmentation strategy be maintained? A 1-year follow up of a placebo-controlled study in unipolar refractory major depression. J. Clin. Psychopharmacol.22, 427–430 (2002).
   PubMed Web of Science ®Google Scholar
• Müller-Oerlinghausen B, Ahrens B, Felber W. The suicide-preventive and mortality-reducing effect of lithium. In: Lithium in Neuropsychiatry. The Comprehensive Guide. Bauer M, Grof P, Müller-Oerlinghausen B (Eds). Informa Healthcare, London, UK, 179–192 (2006).
   Google Scholar
• Lauterbach E, Felber W, Müller-Oerlinghausen B et al. Adjunctive lithium treatment in the prevention of suicidal behaviour in depressive disorders: a randomised, placebo-controlled, 1-year trial. Acta Psychiatr. Scand.118, 469–479 (2008).
   PubMed Web of Science ®Google Scholar
• Papakostas GI, Shelton RC, Smith J, Fava M. Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis. J. Clin. Psychiatry68, 826–31 (2007).
   PubMed Web of Science ®Google Scholar
• Bobo WV, Shelton RC. Olanzapine and fluoxetine combination therapy for treatment-resistant depression: review of efficacy, safety, and study design issues. Neuropsychiatr. Dis. Treat.5, 369–383 (2009).
   PubMed Web of Science ®Google Scholar
• Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am. J. Psychiatry166, 980–991 (2009).
   PubMed Web of Science ®Google Scholar
• Adli M, Baethge C, Heinz A, Langlitz N, Bauer M. Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review. Eur. Arch. Psychiatry Clin. Neurosci.255, 387–400 (2005).
   PubMed Web of Science ®Google Scholar
• Ruhé HG, Booij J, v Weert HC et al. Evidence why paroxetine dose escalation is not effective in major depressive disorder: a randomized controlled trial with assessment of serotonin transporter occupancy. Neuropsychopharmacology34, 999–1010 (2009).
   PubMed Web of Science ®Google Scholar
• Bschor T, Hartung HD. Combination of antidepressants. In: Treatment Manual of Therapy Resistant Depression. Pharmacotherapy – Somatic Treatment Strategies – Psychotherapy [in German]. Bschor T (Ed.). Kohlhammer Publisher, Stuttgart, Germany, 86–101 (2008).
   Google Scholar
• Nelson JC. Augmentation and combination strategies in resistant depression. J. Clin. Psychiatry70, e20 (2009).
   PubMedGoogle Scholar
• UK Electroconvulsive Therapy Review Group. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet361, 799–808 (2003).
   PubMed Web of Science ®Google Scholar
• Sackeim HA, Haskett RF, Mulsant BH et al. Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial. JAMA285, 1299–1307 (2001).
   PubMed Web of Science ®Google Scholar
• Sackeim HA, Prudic J, Devanand DP et al. A prospective, randomized, double-blind comparison of bilateral and right unilateral electroconvulsive therapy at different stimulus intensities. Arch. Gen. Psychiatry57, 425–434 (2000).
   PubMed Web of Science ®Google Scholar
• Berger M, van Calker D, Riemann D. Sleep and manipulations of the sleep–wake rhythm in depression. Acta Psychiatr. Scand. Suppl 418, 83–91 (2003).
   PubMedGoogle Scholar
• Golden RN, Gaynes BN, Ekstrom RD et al. The efficacy of light therapy in the treatment of mood disorders: a review and meta-analysis of the evidence. Am. J. Psychiatry62, 656–662 (2005).
   Google Scholar
• Tuunainen A, Kripke DF, Endo T. Light therapy for non-seasonal depression. Cochrane Database Syst. Rev.CD004050 (2004).
   Google Scholar
• Demitrack MA, Thase ME. Clinical significance of transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant depression: synthesis of recent data. Psychopharmacol. Bull.42, 5–38 (2009).
   PubMedGoogle Scholar
• Loo CK, Mitchell PB. A review of the efficacy of transcranial magnetic stimulation (TMS) treatment for depression, and current and future strategies to optimize efficacy. J. Affect. Disord.88, 255–267 (2005).
   PubMed Web of Science ®Google Scholar
• Rush AJ, Marangell LB, Sackeim HA et al. Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. Biol. Psychiatry58, 347–354 (2005).
   PubMed Web of Science ®Google Scholar
• Daban C, Martinez-Aran A, Cruz N, Vieta E. Safety and efficacy of vagus nerve stimulation in treatment-resistant depression. A systematic review. J. Affect. Disord.110, 1–15 (2008).
   PubMed Web of Science ®Google Scholar
• Rush AJ, Siefert SE. Clinical issues in considering vagus nerve stimulation for treatment-resistant depression. Exp. Neurol.219, 36–43 (2009).
   PubMed Web of Science ®Google Scholar
• Keller MB, McCullough JP, Klein DN et al. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N. Engl J. Med.342, 1462–1470 (2000).
   PubMed Web of Science ®Google Scholar
• McCullough JP. Treatment for chronic depression using Cognitive Behavioral Analysis System of Psychotherapy (CBASP). J. Clin. Psychol.59, 833–846 (2003).
   PubMed Web of Science ®Google Scholar
• Adli M, Bauer M, Rush AJ. Algorithms and collaborative-care systems for depression: are they effective and why? A systematic review. Biol. Psychiatry59, 1029–1038 (2006).
   PubMed Web of Science ®Google Scholar
• Adli M, Wiethoff K, Baghai TC et al. Evaluating algorithm-guided treatment for depression: the German Algorithm Project (GAP). Pharmacopsychiatry38, A002 (2005).
   Google Scholar
• Malone DA Jr, Dougherty DD, Rezai AR et al. Deep brain stimulation of the ventral capsule/ventral striatum for treatment-resistant depression. Biol. Psychiatry65, 267–275 (2009).
   PubMed Web of Science ®Google Scholar